Immune Adjuvant Effect of a Toxoplasma Gondii Profilin-like Protein in Autologous Whole-tumor-cell Vaccination in Mice

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Oct 1

PMID 27687589

Citations 13

Authors

Kyoung-Ho Pyo

You-Won Lee

Sun Min Lim

Eun-Hee Shin

Affiliations

Soon will be listed here.

Abstract

Profilin-like protein in Toxoplasma gondii (TgPLP) is a Toll-like receptor (TLR) agonist. In this study, we investigated whether TgPLP has an adjuvant effect on immune function in autologous whole-tumor-cell vaccine (AWV) treatment. Mice vaccinated with AWV together with recombinant TgPLP protein had smaller CT26 tumors and increased survival. TgPLP treatment strongly increased the production of IL-12 through MyD88 signaling and several chemokines, including CCL5, CCL12, and XCL1, in bone marrow-derived macrophages (BMMs). In addition, TgPLP increased the phagocytosis of tumor cells by BMMs and promoted immune cell mobility on a tumor-matrigel scaffold. TgPLP triggered immune responses as demonstrated by increased expression of antigen presenting cell markers (MHC class I and II, B7.1, and B7.2) in BMMs and increased IL-12 and IFN-γ expression in mice. Mice vaccinated with AWV and TgPLP had more immune cells (CD4+ and CD8+ T cells, natural killer cells, and macrophages) in the spleen and higher total IgG and IgG2a concentrations in the blood than mice vaccinated with AWV alone. These findings suggest that TgPLP is a TLR-based vaccine adjuvant that enhances antitumor immune responses during vaccination with AWV.

Citing Articles

Parasites revive hope for cancer therapy.

Eissa M, Salem A, El Skhawy N Eur J Med Res. 2024; 29(1):489.

PMID: 39367471 PMC: 11453045. DOI: 10.1186/s40001-024-02057-2.

Toxoplasma gondii suppresses proliferation and migration of breast cancer cells by regulating their transcriptome.

Ye H, Zhou X, Zhu B, Xiong T, Huang W, He F Cancer Cell Int. 2024; 24(1):144.

PMID: 38654350 PMC: 11040860. DOI: 10.1186/s12935-024-03333-1.

Exploiting the Macrophage Production of IL-12 in Improvement of Vaccine Development against and Infections.

Fereig R, Omar M, Alsayeqh A Vaccines (Basel). 2022; 10(12).

PMID: 36560492 PMC: 9783364. DOI: 10.3390/vaccines10122082.

infection possibly reverses host immunosuppression to restrain tumor growth.

Chen J, Liao W, Peng H Front Cell Infect Microbiol. 2022; 12:959300.

PMID: 36118042 PMC: 9470863. DOI: 10.3389/fcimb.2022.959300.

causes changes in the host's expression of cancer-associated miRNAs.

Wang L, Wang N, Zhao Y, Lu G Oncol Lett. 2022; 23(5):149.

PMID: 35350589 PMC: 8941548. DOI: 10.3892/ol.2022.13267.

References

Gonzalez R, Shehata H, OConnell M, Yang Y, Moreno-Fernandez M, Chougnet C . Toxoplasma gondii- derived profilin triggers human toll-like receptor 5-dependent cytokine production. J Innate Immun. 2014; 6(5):685-94. PMC: 4141014. DOI: 10.1159/000362367. View

Robertson M . Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002; 71(2):173-83. View

Yarovinsky F . Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol. 2014; 14(2):109-21. DOI: 10.1038/nri3598. View

Halonen S, Weiss L . Toxoplasmosis. Handb Clin Neurol. 2013; 114:125-45. PMC: 4157368. DOI: 10.1016/B978-0-444-53490-3.00008-X. View

Butowski N, Chang S, Junck L, DeAngelis L, Abrey L, Fink K . A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2008; 91(2):175-82. PMC: 4779120. DOI: 10.1007/s11060-008-9693-3. View

Araki-Sasaki K, Tanaka T, Ebisuno Y, Kanda H, Umemoto E, Hayashi K . Dynamic expression of chemokines and the infiltration of inflammatory cells in the HSV-infected cornea and its associated tissues. Ocul Immunol Inflamm. 2006; 14(5):257-66. DOI: 10.1080/09273940600943581. View

Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg M, Quest A, Kiessling R . DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther. 2010; 19(3):594-601. PMC: 3048184. DOI: 10.1038/mt.2010.268. View

Rankin E, Yu D, Jiang J, Shen H, Pearce E, Goldschmidt M . An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biol Ther. 2003; 2(6):687-93. View

Hofmann M, Kors C, Audring H, Walden P, Sterry W, Trefzer U . Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother. 2008; 31(5):520-7. DOI: 10.1097/CJI.0b013e318174a4df. View

10.

Gazzinelli R, Wysocka M, Hayashi S, Denkers E, Hieny S, Caspar P . Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol. 1994; 153(6):2533-43. View

11.

Komai T, Okamura T, Yamamoto K, Fujio K . The effects of TGF-βs on immune responses. Nihon Rinsho Meneki Gakkai Kaishi. 2016; 39(1):51-8. DOI: 10.2177/jsci.39.51. View

12.

Engel M, Neurath M . Anticancer properties of the IL-12 family--focus on colorectal cancer. Curr Med Chem. 2010; 17(29):3303-8. DOI: 10.2174/092986710793176366. View

13.

Toussi D, Massari P . Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines (Basel). 2015; 2(2):323-53. PMC: 4494261. DOI: 10.3390/vaccines2020323. View

14.

Weiss E, Wunderlich R, Ebel N, Rubner Y, Schlucker E, Meyer-Pittroff R . Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol. 2012; 2:132. PMC: 3466463. DOI: 10.3389/fonc.2012.00132. View

15.

Smorlesi A, Papalini F, Orlando F, Donnini A, Re F, Provinciali M . Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther. 2005; 12(17):1324-32. DOI: 10.1038/sj.gt.3302559. View

16.

Speiser D, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W . Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010; 33(8):848-58. DOI: 10.1097/CJI.0b013e3181f1d614. View

17.

Schulze H, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Diez A . Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005; 152(5):939-47. DOI: 10.1111/j.1365-2133.2005.06486.x. View

18.

Pyo K, Jung B, Xin C, Lee Y, Chai J, Shin E . Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatment. Korean J Parasitol. 2014; 52(6):605-12. PMC: 4277022. DOI: 10.3347/kjp.2014.52.6.605. View

19.

Seledtsov V, Goncharov A, Seledtsova G . Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum Vaccin Immunother. 2015; 11(4):851-69. PMC: 4514272. DOI: 10.1080/21645515.2015.1009814. View

20.

Krummen M, Balkow S, Shen L, Heinz S, Loquai C, Probst H . Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. J Leukoc Biol. 2010; 88(1):189-99. DOI: 10.1189/jlb.0408228. View